Mixed phenotype acute leukemia

Summary

Mixed phenotype acute leukemia (MONDO:0020743) is a cancer and 56 clinical trials. Top therapeutic interventions include daunorubicin, mercaptopurine anhydrous, and calaspargase pegol. A subtype of acute leukemia of ambiguous lineage — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Prevalence: Unknown (Worldwide) [Orphanet-validated]
• Clinical trials: 56

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	mixed phenotype acute leukemia
Mondo ID	MONDO:0020743
Orphanet	530995
NCIT	C82179
UMLS	C2826025
MedGen	417342
GARD	0017972
MedDRA	10067399
Is cancer (heuristic)	yes

Also known as: mixed phenotype acute leukemia · MPAL

Data availability: 6 cell lines.

Disease family

This is a subtype of acute leukemia of ambiguous lineage. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › hematopoietic and lymphoid system neoplasm › hematopoietic and lymphoid cell neoplasm › leukemia › myeloid leukemia › acute myeloid leukemia › acute leukemia of ambiguous lineage › mixed phenotype acute leukemia

Related subtypes (2): bilineal acute myeloid leukemia, acute undifferentiated leukemia

Subtypes (3): acute biphenotypic leukemia, mixed phenotype acute leukemia with t(9;22)(q34.1;q11.2), mixed phenotype acute leukemia with t(v;11q23.3)

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 56.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	16
PHASE1	16
PHASE1/PHASE2	13
PHASE3	6
Not specified	3
PHASE4	1
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06289673	PHASE4	RECRUITING	Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma
NCT03007147	PHASE3	ACTIVE_NOT_RECRUITING	Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
NCT03959085	PHASE3	RECRUITING	Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
NCT05316701	PHASE3	ACTIVE_NOT_RECRUITING	Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
NCT05327894	PHASE3	RECRUITING	Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia
NCT05457556	PHASE3	ACTIVE_NOT_RECRUITING	Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome
NCT05602194	PHASE3	ACTIVE_NOT_RECRUITING	Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma
NCT03128034	PHASE1/PHASE2	RECRUITING	211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia
NCT03670966	PHASE1/PHASE2	RECRUITING	211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
NCT03779854	PHASE2	RECRUITING	Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant
NCT04065399	PHASE1/PHASE2	RECRUITING	A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
NCT04067336	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia
NCT04128501	PHASE2	ACTIVE_NOT_RECRUITING	Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting
NCT04195633	PHASE2	RECRUITING	Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
NCT04726241	PHASE1/PHASE2	RECRUITING	The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children’s Oncology Group Study
NCT04797767	PHASE1/PHASE2	RECRUITING	Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms
NCT04904588	PHASE2	ACTIVE_NOT_RECRUITING	HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide
NCT05761171	PHASE2	ACTIVE_NOT_RECRUITING	A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia
NCT06013423	PHASE2	RECRUITING	Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
NCT06390319	PHASE2	RECRUITING	Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)
NCT06533579	PHASE1/PHASE2	RECRUITING	Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
NCT06928662	PHASE1/PHASE2	RECRUITING	Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse
NCT07216443	PHASE2	RECRUITING	Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
NCT07222579	PHASE2	RECRUITING	Subcutaneous Blinatumomab for Treatment of Adult Patients With CD19-Positive Mixed Phenotype Acute Leukemia (MPAL)
NCT07256210	PHASE2	RECRUITING	Feasibility and Safety of Donor-derived NK-cell Infusions for Leukemia Relapse Prophylaxis After Hematopoietic Stem Cell Transplantation
NCT07356154	PHASE1/PHASE2	RECRUITING	A Study of Revumenib and Mezigdomide in People With Leukemia
NCT00723099	PHASE2	COMPLETED	Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer
NCT02135874	PHASE2	COMPLETED	Clofarabine, Idarubicin, Cytarabine, Vincristine Sulfate, and Dexamethasone in Treating Patients With Newly Diagnosed or Relapsed Mixed Phenotype Acute Leukemia
NCT02828358	PHASE2	COMPLETED	Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement
NCT02921061	PHASE1/PHASE2	COMPLETED	Decitabine With GCLAM for Adults With Newly Diagnosed, Relapsed, or Refractory AML or High-Risk MDS
NCT03404193	PHASE2	TERMINATED	Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome
NCT04762485	PHASE1/PHASE2	UNKNOWN	Humanized CD7 CAR T-cell Therapy for r/r CD7+ Acute Leukemia
NCT04827745	PHASE2	COMPLETED	Blinatumomab for Treatment of R/R or MRD-positive CD19-Positive MPAL
NCT05320380	PHASE1/PHASE2	WITHDRAWN	A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment or is Difficult to Treat
NCT05322850	PHASE1/PHASE2	SUSPENDED	Phase I/II Trial: Engineered Donor Graft (Orca Q) for Pediatric Hematopoietic Cell Transplant (HCT)
NCT05433532	PHASE2	COMPLETED	Study of Azacitidine，Venetoclax，and Flumatinib in Newly Diagnosed Ph-positive Acute Leukemia and CML-AP/BP Patients
NCT02879695	PHASE1	ACTIVE_NOT_RECRUITING	Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia
NCT03326921	PHASE1	RECRUITING	HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
NCT03802695	PHASE1	RECRUITING	A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
NCT03843528	PHASE1	ACTIVE_NOT_RECRUITING	Vorinostat Dose-escalation After Allogeneic Hematopoietic Cell Transplantation

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
DAUNORUBICIN	4	9
MERCAPTOPURINE ANHYDROUS	4	6
CALASPARGASE PEGOL	4	5
REVUMENIB	4	5
PEGASPARGASE	4	4
THIOGUANINE	4	4
BLINATUMOMAB	4	3
CLADRIBINE	4	3
DEXRAZOXANE	4	3
HYDROCORTISONE SODIUM SUCCINATE	4	3
IMATINIB	4	3
MYCOPHENOLATE SODIUM	4	2
BUSULFAN	4	1
CLOFARABINE	4	1
COBICISTAT	4	1
CYTARABINE	4	1
HYDROCORTISONE	4	1
IFOSFAMIDE	4	1
INOTUZUMAB OZOGAMICIN	4	1
ITRACONAZOLE	4	1
IXAZOMIB CITRATE	4	1
LEVOCARNITINE	4	1
LEVOLEUCOVORIN	4	1
MELPHALAN	4	1
MITOXANTRONE HYDROCHLORIDE	4	1
NELARABINE	4	1
SORAFENIB TOSYLATE	4	1
TAGRAXOFUSP	4	1
THIOTEPA	4	1
TREOSULFAN	4	1